Original Article

Licochalcone A Inhibits Proliferation and Metastasis of Colon Cancer by Regulating miR-1270/ADAM9/Akt/NF-κB axis


Background: We aimed to explor the therapeutic effect and molecular mechanism of licochalcone A (LCA) on colon cancer.

Methods: This study was carried out in 2020-2021 in Nanjing Tongren Hospital, China. Colon cancer HCT116 cells were treated with different concentrations of LCA. Cell counting kit-8, colony formation and flow cytometry assays were used to analyze cell viability, proliferation and apoptosis. Wound healing and transwell experiments were used to measure cell migration and invasion ability. The expression of ADAM9 and apoptosis-related proteins in different LCA treatment groups was detected by western blot. HCT116 cells were transfected with ADAM9 small interfering RNAs (siRNAs) or overexpression vectors. The database screened the upstream miRNA targeting ADAM9 and predicted the targeted binding site between miR-1270 and ADAM9, which was verified by a dual-luciferase reporter assay. Rescue experiments were performed to confirm the effects of the miR-1270/ADAM9 axis on cell proliferation and metastasis.

Results: LCA decreased cell growth (P<0.05), migration (P<0.05), and invasion (P<0.05) of colon cancer cells and inhibited ADAM9 expression in a dose-dependent manner. LCA affected the functions of colon cancer cells by negatively regulating the expression of ADAM9. MiR-1270, increased by LCA, targeted and suppressed ADAM9 expression significantly (P<0.001). ADAM9 overexpression restrained miR-1270 mimic and LCA-induced changes in cell proliferation, migration, and invasion, and promoted apoptosis in HCT116 cells significantly (P<0.01). LCA and miR-1270 mimic inactivated the Akt/NF-κB pathway, while ADAM9 overexpression rescued it.

Conclusion: LCA exhibited antitumor efficacy in HCT116 cells by inhibiting the Akt/NF-κB signaling pathway by regulating the miR-1270/ADAM9 axis.


1. Siegel RL, Miller KD, Jemal A (2022). Can-cer statistics, 2020. CA Cancer J Clin, 72 (1):7-30.
2. Shibata S (2000). A drug over the millennia: pharmacognosy, chemistry, and pharma-cology of licorice. Yakugaku Zasshi, 120(10):849-862.
3. He W, Wu JJ, Ning J, et al (2015). Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring con-stituent of licorice. Toxicol In Vitro, 29(7):1569-1576.
4. Wittschier N, Faller G, Hensel A (2009). Aqueous extracts and polysaccharides from liquorice roots (Glycyrrhiza glabra L.) inhibit adhesion of Helicobacter pylori to human gastric mucosa. J Ethnopharmacol, 125 (2): 218-223.
5. Kolbe L, Immeyer J, Batzer J, et al (2006). Anti-inflammatory efficacy of Licochal-cone A: correlation of clinical potency and in vitro effects. Arch Dermatol Res, 298(1):23-30.
6. Fu Y, Chen J, Li YJ, Zheng YF, Li P (2013). Antioxidant and anti-inflammatory activi-ties of six flavonoids separated from lico-rice. Food Chem, 141(2):1063-1071.
7. Mi-Ichi F, Miyadera H, Kobayashi T, et al (2005). Parasite mitochondria as a target of chemotherapy: inhibitory effect of licochalcone A on the Plasmodium falci-parum respiratory chain. Ann N Y Acad Sci, 1056:46-54.
8. Liu X, Xing Y, Li M, et al (2021). Licochal-cone A inhibits proliferation and pro-motes apoptosis of colon cancer cell by targeting programmed cell death-ligand 1 via the NF-κB and Ras/Raf/MEK path-ways. J Ethnopharmacol, 273:113989.
9. Huang CF, Yang SF, Chiou HL, et al (2018). Licochalcone A inhibits the invasive po-tential of human glioma cells by targeting the MEK/ERK and ADAM9 signaling pathways. Food Funct, 9 (12): 6196-6204.
10. Silva LM, Marconato DG, Nascimento da Silva MP, et al (2021). Licochalcone A-loaded solid lipid nanoparticles improve antischistosomal activity in vitro and in vivo. Nanomedicine (Lond), 16(18):1641-1655.
11. Nath D, Slocombe PM, Webster A, (2000). Meltrin gamma(ADAM-9) mediates cellu-lar adhesion through alpha(6)beta(1 )in-tegrin, leading to a marked induction of fibroblast cell motility. J Cell Sci, 113 (Pt 12):2319-2328.
12. Seals DF, Courtneidge SA (2003). The AD-AMs family of metalloproteases: mul-tidomain proteins with multiple func-tions. Genes Dev, 17(1):7-30.
13. Lin Q, Jia Y, Zhang D, Jin H (2021). NCK1-AS1 promotes the progression of melanoma by accelerating cell prolifera-tion and migration via targeting miR-526b-5p/ADAM15 axis. Cancer Cell Int, 2(1):367.
14. Zhou R, Cho WCS, Ma V, et al (2020). ADAM9 mediates triple-negative breast cancer progression via AKT/NF-κB pathway. Front Med (Lausanne), 7:214.
15. Ma D, Zhu Y, Zhang X, et al (2021). Long non-coding RNA RUNDC3A-AS1 promotes lung metastasis of thyroid can-cer via targeting the miR-182-5p/ADAM9. Front Cell Dev Biol, 9:650004.
16. Liu B, Wang R, Liu H (2021). mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9. Biomed Res Int, 2021:6622342.
17. Zhang YY, Li SQ, Song Y, et al (2022). Si-lencing the ADAM9 Gene through CRISPR/Cas9 Protects Mice from Alco-hol-Induced Acute Liver Injury. Biomed Res Int, 2022:5110161.
18. Hou C, Sun F, Sun M (2021). Long non-coding RNA ASMTL-AS1 deteriorates the oncogenicity of osteosarcoma by de-coying microRNA-342–3p and conse-quently raising ADAM9 expression. Bio-chem Bioph Res Co, 579: 89-96.
19. Li J, Ji Z, Qiao C, Qi Y, Shi W (2013). Over-expression of ADAM9 promotes colon cancer cells invasion. J Invest Surg, 26(3):127-133.
20. Huang WC, Su HH, Fang LW, Wu SJ, Liou CJ (2019). Licochalcone A Inhibits Cellu-lar Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer. Cells, 8(3):218.
21. Zhou M, Qin B, Deng XS, et al (2019). hNTCP‑expressing primary pig hepato-cytes are a valuable tool for investigating hepatitis B virus infection and antiviral drugs. Mol Med Rep, 20(4):3820-3828.
22. Hong SH, Cha HJ, Hwang-Bo H, et al (2019). Anti-proliferative and pro-apoptotic effects of Licochalcone A through ROS-Mediated cell cycle arrest and apoptosis in human bladder cancer cells. Int J Mol Sci, 20(15):3820.
23. Wu P, Yu T, Wu J, Chen J (2020). Licochal-cone a induces ROS-mediated apoptosis through TrxR1 inactivation in colorectal cancer cells. Biomed Res Int, 2020:5875074.
24. Lu WJ, Wu GJ, Chen RJ, et al (2018). Lico-chalcone A attenuates glioma cell growth in vitro and in vivo through cell cycle ar-rest. Food Funct, 9(8):4500-4507.
25. Chou CW, Huang YK, Kuo TT, Liu JP, Sher YP (2020). An Overview of AD-AM9: Structure, Activation, and Regula-tion in Human Diseases. Int J Mol Sci, 21(20):7790.
26. Chen CM, Hsieh YH, Hwang JM, et al (2015). Fisetin suppresses ADAM9 ex-pression and inhibits invasion of glioma cancer cells through increased phosphor-ylation of ERK1/2. Tumor Biol, 36(5): 3407-3415.
27. Lu P, Chen J, Yan L, et al (2019). RasGRF2 promotes migration and invasion of col-orectal cancer cells by modulating expres-sion of MMP9 through Src/Akt/NF-κB pathway. Cancer Biol Ther, 20(4):435-443.
28. Jung EJ, Paramanantham A, Kim HJ, et al (2022). Identification of growth factors, cytokines and mediators regulated by Ar-temisia annua L. polyphenols (pKAL) in HCT116 colorectal cancer cells: TGF-β1 and NGF-β attenuate pKAL-induced an-ticancer effects via NF-κB p65 upregula-tion. Int J Mol Sci, 23(3):1598.
29. Song Z, Wang J (2022). LncRNA ASMTL-AS1/microRNA-1270 differentiate prog-nostic groups in gastric cancer and influ-ence cell proliferation, migration and in-vasion. Bioengineered, 13(1):1507-1517.
IssueVol 52 No 9 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v52i9.13578
Licochalcone A Colon cancer miR-1270 ADAM9 Akt/NF-κB pathway

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Pan C, Chen H, Yang B. Licochalcone A Inhibits Proliferation and Metastasis of Colon Cancer by Regulating miR-1270/ADAM9/Akt/NF-κB axis. Iran J Public Health. 2023;52(9):1962-1972.